CureVac price target lowered to $24 from $34 at JMP Securities

JMP Securities lowered the firm’s price target on CureVac to $24 from $34 and keeps an Outperform rating on the shares. CureVac’s FY22 results were somewhat behind consensus estimates, and while the oncology programs remain largely on track, there is a revision to the planned melanoma trial, which is now anticipated to start in 2024, vs. in 2H23 previously, the analyst tells investors in a research note.